• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Gleckel Louis Md

    3/19/24 9:49:45 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRPH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    GLECKEL LOUIS MD

    (Last) (First) (Middle)
    711 STEWART AVENUE,
    SUITE 200

    (Street)
    GARDEN CITY, NY 11530

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ProPhase Labs, Inc. [ PRPH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/17/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Option (right to buy) $6 03/17/2024 A 70,000 (1) 03/17/2031 Common Stock 70,000 $0 70,000 D
    Explanation of Responses:
    1. Options shall vest and become exercisable in four equal installments, with 25% of such award vesting and becoming exercisable on each of September 30, 2024, December 31, 2024, March 31, 2025 and June 30, 2025 provided the recipient continues to serve as a non-employee director of the Issuer on each such vesting date.
    /s/ Louis Gleckel 03/19/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PRPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRPH

    DatePrice TargetRatingAnalyst
    1/14/2022$12.00 → $15.00Buy
    HC Wainwright & Co.
    12/20/2021$12.00Buy
    HC Wainwright & Co.
    10/13/2021Buy → Neutral
    Dawson James
    More analyst ratings

    $PRPH
    Leadership Updates

    Live Leadership Updates

    See more
    • ProPhase Labs hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports

      GARDEN CITY, NY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and consumer products company, today announced the appointment of Stu Hollenshead as Chief Operating Officer, marking a pivotal step in the company's expansion into consumer-centered health and wellness products. As COO, Hollenshead will focus on accelerating ProPhase Labs' consumer-facing strategy, leveraging his deep expertise in direct-to-consumer growth, subscription models, digital marketing, and audience monetization to position the company as a leader in science-backed health solutions. The Company plans to provide additional updat

      2/18/25 8:00:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase Labs Unveils Project ZenQ-AI

      Leveraging ProPhase Labs' AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company's state-of-the-art AI platform which was meticulously developed with leading AI technology platforms and systems. The Company is harnessing its extensive genomic database—built over the last six years from whole genome sequencing tests (W

      4/16/24 8:00:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sidus Space Appoints Bill White as Chief Financial Officer

      Sidus Space (NASDAQ:SIDU) (the "Company" or "Sidus"), a multi-faceted Space and Data-as-a-Service company, today announced the appointment of Bill White as Chief Financial Officer, effective February 20, 2024. Mr. White will oversee the Company's accounting, financial planning, capital raise, treasury, legal and regulatory functions. Mr. White has more than 30 years of experience in financial management, operations, and business development. He most recently served as Chief Financial Officer of ProPhase Labs, Inc. (NASDAQ:PRPH) and prior to ProPhase he was CFO, treasurer, and secretary of Intellicheck, Inc., a technology company listed on the NasdaqGM. Mr. White has broad domestic and int

      2/8/24 8:30:00 AM ET
      $PRPH
      $SIDU
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Telecommunications Equipment
      Telecommunications

    $PRPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

      SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

      3/19/24 4:18:00 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

      SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

      4/5/23 4:37:55 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

      SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

      4/4/23 4:25:33 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $PRPH
    Financials

    Live finance-specific insights

    See more
    • ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2025

      Highlights Multiple Significant Potential Liquidity Events Anticipated Within the Next Few Months Completes Significant Reductions in Overhead and Expenses BE-Smart Esophageal Cancer Test Study has been Submitted in the Journal of Clinical Gastrointestinal Hepatology Company to hold a virtual conference call Tuesday, May 20, 2025, at 10:00 AM ET GARDEN CITY, NY, May 20, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, today reported its financial and operational results for Q1 ended March 31, 2025, and outlined significant strategic corporate developments. Ted Karkus, CEO of ProP

      5/20/25 8:00:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025

      GARDEN CITY, NY, May 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, announced today that they will be presenting first quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on May 20, 2025, at 10:00 am EDT. Ted Karkus, CEO, looks forward to providing shareholders with an update on several positive activities, including the initiative to sell the Company's wholly owned subsidiary, Nebula Genomics, and the Crown Medical Collections initiative to collect tens of millions of dollars in accounts receivable. A press release detailing these results wi

      5/13/25 8:00:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024

      Company to Accelerate BE-Smart Commercialization as a Cash-Pay Diagnostic Significantly reduces overhead, improves margins heading into Q2 2025 Company to hold a conference call Monday, March 31, 2025, at 11:00 AM EST GARDEN CITY, NY, March 31, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase"), a next generation biotech, genomics and consumer products company, today reported its financial and operational results for the full-year ended December 31, 2024 and outlined strategic corporate developments aimed at realigning the Company for sustained long-term growth, profitability, and strategic focus. Ted Karkus, CEO of ProPhase Labs, will present to

      3/31/25 8:00:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2025

      Highlights Multiple Significant Potential Liquidity Events Anticipated Within the Next Few Months Completes Significant Reductions in Overhead and Expenses BE-Smart Esophageal Cancer Test Study has been Submitted in the Journal of Clinical Gastrointestinal Hepatology Company to hold a virtual conference call Tuesday, May 20, 2025, at 10:00 AM ET GARDEN CITY, NY, May 20, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, today reported its financial and operational results for Q1 ended March 31, 2025, and outlined significant strategic corporate developments. Ted Karkus, CEO of ProP

      5/20/25 8:00:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025

      GARDEN CITY, NY, May 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, announced today that they will be presenting first quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on May 20, 2025, at 10:00 am EDT. Ted Karkus, CEO, looks forward to providing shareholders with an update on several positive activities, including the initiative to sell the Company's wholly owned subsidiary, Nebula Genomics, and the Crown Medical Collections initiative to collect tens of millions of dollars in accounts receivable. A press release detailing these results wi

      5/13/25 8:00:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025

      GARDEN CITY, NY, March 27, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase"), a next generation biotech, genomics and consumer products company, today announced that they will be presenting full year 2024 financial results, and a review of current Company strategy, on a virtual conference call hosted by Renmark Financial on March 31, 2025 at 11:00 AM EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event. Investors interested in participating in this live event will need to register usin

      3/27/25 8:27:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer Hollenshead Stuart

      4 - ProPhase Labs, Inc. (0000868278) (Issuer)

      2/21/25 5:15:08 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Hollenshead Stuart

      3 - ProPhase Labs, Inc. (0000868278) (Issuer)

      2/21/25 5:00:11 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Gleckel Louis Md

      4 - ProPhase Labs, Inc. (0000868278) (Issuer)

      2/18/25 5:00:13 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRPH
    SEC Filings

    See more
    • SEC Form 10-Q filed by ProPhase Labs Inc.

      10-Q - ProPhase Labs, Inc. (0000868278) (Filer)

      5/20/25 4:06:42 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ProPhase Labs, Inc. (0000868278) (Filer)

      5/20/25 8:00:55 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-Q filed by ProPhase Labs Inc.

      NT 10-Q - ProPhase Labs, Inc. (0000868278) (Filer)

      5/16/25 5:00:09 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on ProPhase Labs with a new price target

      HC Wainwright & Co. reiterated coverage of ProPhase Labs with a rating of Buy and set a new price target of $15.00 from $12.00 previously

      1/14/22 6:36:15 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on ProPhase Labs with a new price target

      HC Wainwright & Co. initiated coverage of ProPhase Labs with a rating of Buy and set a new price target of $12.00

      12/20/21 6:25:15 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase downgraded by Dawson James

      Dawson James downgraded ProPhase from Buy to Neutral

      10/13/21 10:48:44 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care